Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.
about
Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.Widespread amphotericin B-resistant strains of in Hamilton, CanadaTreatment of Aspergillosis
P2860
Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Susceptibility breakpoints for ...... concentrations in human serum.
@ast
Susceptibility breakpoints for ...... concentrations in human serum.
@en
type
label
Susceptibility breakpoints for ...... concentrations in human serum.
@ast
Susceptibility breakpoints for ...... concentrations in human serum.
@en
prefLabel
Susceptibility breakpoints for ...... concentrations in human serum.
@ast
Susceptibility breakpoints for ...... concentrations in human serum.
@en
P2093
P2860
P356
P1476
Susceptibility breakpoints for ...... concentrations in human serum
@en
P2093
A Elefanti
J Meletiadis
J W Mouton
P2860
P304
P356
10.1128/AAC.02661-13
P407
P577
2014-02-10T00:00:00Z